Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Sickle cell disease: when to transfuse
source: Medscape
year: 2018
authors: Mary Hulihan
summary/abstract:Hello. I am Dr Mary Hulihan, a health scientist in the Division of Blood Disorders at the Centers for Disease Control and Prevention. Today I would like to talk about the indications for blood transfusion in patients with sickle cell disease, the complications associated with these transfusions, and how you can help reduce the risk for these complications in your patients.
For many patients with sickle cell disease, red blood cell transfusions are an important part of medical care, reducing both mortality and morbidity. Both the National Heart, Lung, and Blood Institute and the British Society for Haematology have published documents that underscore the many unique aspects of care that must be taken into account when transfusing this patient population.
Although transfusions can be highly beneficial in treating sickle cell disease–related issues, they are not without risks. There are three scenarios when blood transfusions should be considered for patients with sickle cell disease. First, certain acute illnesses, such as acute chest syndrome or severe exacerbation of anemia with splenic or hepatic sequestration, may call for a simple blood transfusion.
read moreRelated Content
-
HHS Secretary Alex Azar Touts White House Efforts to Fight Sickle Cell DiseaseBy 2029, Americans with sickle cell dise...
-
Antibiotic prophylaxis for children with sickle cell anemiaBACKGROUND: Children with sickle cell an...
-
The Life, Death, and Dream of a Research Diversity Crusader“We want to have a nation in which the...
-
Hemoglobin A1c and Fructosamine Correlate in a Patient With Sickle Cell Disease And Diabetes on Chronic Transfusion ...In patients with sickle cell disease (SC...
-
CTX001 Continues to Show Promise in Severe SCDA single dose of CTX001, an experimental...
-
Potential treatment targeting nitric oxide levels, olinciguat, named orphan drug by FDAThe U.S. Food and Drug Administration ...
-
Bluebird Bio Presents Data From LentiGlobin Gene Therapy TrialBluebird Bio’s investigational gene th...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
+myBinder